- Molecular NameMetixene
- SynonymMethixen [German]; Methixene; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Metixeno [INN-Spanish]; Metixenum [INN-Latin]
- Weight309.477
- Drugbank_IDDB00340
- ACS_NO4969-02-2
- Show 3D model
- LogP (experiment)5.7
- LogP (predicted, AB/LogP v2.0)5.36
- pkaN/A
- LogD (pH=7, predicted)2.7
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.24
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors0
- No.of HBond Acceptors1
- No.of Rotatable Bonds2
- TPSA28.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyA anticholinergic used as an anti-parkinson drug.
- Absorption_valueN/A
- Absorption (description)Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Metabolism occurs via sulfoxydation and N-demethylation.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
- LD50 (rat)N/A
- LD50 (mouse)N/A